Antineutrophil cytoplasmic antibody-associated vasculitis: insights into relapse risk and future management directions
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has a relapsing-remitting course and, even with the availability of effective maintenance therapies such as rituximab, relapse rates remain high. Relapse is associated with the accrual of organ damage stemming from both the under...
Gardado en:
| Principais autores: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Frontiers Media S.A.
2025-09-01
|
| Series: | Frontiers in Immunology |
| Assuntos: | |
| Acceso en liña: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1655326/full |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|